InvestSMART

Tissue Repair Ltd (ASX:TRP)

ALERT: Price-sensitive ASX Announcement for TRP
Current share price for TRP : $0.088 -0.052 (-37.14%)+
Announcement
Release
30 Apr 2026 2:28PM
Price at Release
$0.140
Full Release
download
Summary
Tissue Repair Limited (ASX:TRP) is advancing its Phase 3 clinical trials for the TR987® drug, aimed at treating chronic wounds, with recruitment accelerating. The company is also working on commercializing the TR Pro+® line for aesthetic and medical procedures, with significant sales achieved in the March quarter. TRP's financial report indicates net operating cash outflows of $1.684 million for the March 2026 quarter and a strong cash position of $6.657 million. The company expects to achieve a milestone of 100 patient randomizations by September 2026 to facilitate interim analysis. Furthermore, regulatory submissions for TR Pro+® are progressing as planned, with anticipated entry into the US, Asian, and European markets. The company maintains an estimated funding runway of four quarters, supported by an expected R&D tax rebate.
Key Points
  • Tissue Repair Limited (ASX:TRP) focuses on Phase 3 clinical trials for TR987® for chronic wounds and commercialises TR Pro+®.
  • Recruitment for the TR987® Phase 3 trial has accelerated with 64 patients randomized and 11 more in screening.
  • TRP is focused on achieving 100 patient randomizations by September 2026 for interim analysis.
  • The progress of US 510(k) and CE mark submissions for TR Pro+® for wound and dermatology indications is on track.
  • Sales of TR Pro+® exceeded 9,000 units in the March quarter, with a major production run scheduled for May 2026.
  • The company reported net operating cash outflows of $1.684 million with a cash position of $6.657 million as of March 31, 2026.
  • Estimated funding runway for the company is approximately four quarters.
  • TRP is set to receive an R&D tax rebate of approximately $2.0 million for FY2025.
  • The company's focus remains on enhancing recruitment for clinical trials and advancing regulatory submissions.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.